NO20061791L - Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin - Google Patents

Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Info

Publication number
NO20061791L
NO20061791L NO20061791A NO20061791A NO20061791L NO 20061791 L NO20061791 L NO 20061791L NO 20061791 A NO20061791 A NO 20061791A NO 20061791 A NO20061791 A NO 20061791A NO 20061791 L NO20061791 L NO 20061791L
Authority
NO
Norway
Prior art keywords
phenylsulfonyl
piperazin
quinoline
polymorphic form
cns
Prior art date
Application number
NO20061791A
Other languages
English (en)
Norwegian (no)
Inventor
Asa Elisabeth Gladwin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20061791L publication Critical patent/NO20061791L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20061791A 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin NO20061791L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322629.7A GB0322629D0 (en) 2003-09-26 2003-09-26 Novel compound
PCT/EP2004/010843 WO2005040124A1 (fr) 2003-09-26 2004-09-23 Nouveau compose

Publications (1)

Publication Number Publication Date
NO20061791L true NO20061791L (no) 2006-04-24

Family

ID=29286934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061791A NO20061791L (no) 2003-09-26 2006-04-24 Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin

Country Status (23)

Country Link
US (1) US20070032504A1 (fr)
EP (1) EP1667975B1 (fr)
JP (1) JP2007506702A (fr)
CN (1) CN1856471A (fr)
AU (1) AU2004283805A1 (fr)
BR (1) BRPI0414678A (fr)
CA (1) CA2540022A1 (fr)
CO (1) CO5680402A2 (fr)
DE (1) DE602004010410T2 (fr)
DK (1) DK1667975T3 (fr)
ES (1) ES2297465T3 (fr)
GB (1) GB0322629D0 (fr)
HR (1) HRP20080055T3 (fr)
IL (1) IL174213A0 (fr)
IS (1) IS8399A (fr)
MA (1) MA28093A1 (fr)
MX (1) MXPA06003375A (fr)
NO (1) NO20061791L (fr)
PL (1) PL1667975T3 (fr)
PT (1) PT1667975E (fr)
RU (1) RU2355681C2 (fr)
WO (1) WO2005040124A1 (fr)
ZA (1) ZA200601453B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2309154C9 (ru) * 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PT1663958E (pt) 2003-09-18 2015-06-01 Virobay Inc Compostos contendo haloalquilo como inibidores de protease de cisteína
MX2007014929A (es) 2005-06-02 2008-02-15 Hoffmann La Roche 3-metansulfonilquinolinas como mejoradores de gaba-b.
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
WO2017202206A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé quinoléine substitué et composition pharmaceutique correspondante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
RU2309154C9 (ru) * 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CN1856471A (zh) 2006-11-01
GB0322629D0 (en) 2003-10-29
HK1094190A1 (en) 2007-03-23
CA2540022A1 (fr) 2005-05-06
PL1667975T3 (pl) 2008-04-30
HRP20080055T3 (en) 2008-02-29
CO5680402A2 (es) 2006-09-29
RU2006114024A (ru) 2007-11-10
AU2004283805A1 (en) 2005-05-06
IS8399A (is) 2006-04-05
EP1667975B1 (fr) 2007-11-28
US20070032504A1 (en) 2007-02-08
ES2297465T3 (es) 2008-05-01
MXPA06003375A (es) 2006-06-08
IL174213A0 (en) 2006-08-01
DK1667975T3 (da) 2008-04-14
EP1667975A1 (fr) 2006-06-14
BRPI0414678A (pt) 2006-11-28
WO2005040124A1 (fr) 2005-05-06
DE602004010410T2 (de) 2008-10-16
PT1667975E (pt) 2008-02-29
ZA200601453B (en) 2007-04-25
MA28093A1 (fr) 2006-08-01
DE602004010410D1 (en) 2008-01-10
RU2355681C2 (ru) 2009-05-20
JP2007506702A (ja) 2007-03-22

Similar Documents

Publication Publication Date Title
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
EA200501274A1 (ru) Пиразолы и способы их получения и применения
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
TW200510317A (en) Caspase inhibitors and uses thereof
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
SE0301368D0 (sv) Chemical compounds
NO20061791L (no) Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004043379A3 (fr) Composes chimiques
GB0322510D0 (en) Novel compounds
SE0300850D0 (sv) Chemical compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
DE60329326D1 (de) Tace inhibitoren
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
SE0200844D0 (sv) Chemical compounds
SE0200843D0 (sv) Chemical compounds
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
SE0300957D0 (sv) Chemical compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application